Education
About Us
Working with TipRanks
Follow Us
Resmed Inc (CH:RME)
:RME
RME Analyst Ratings
Currently, no data available
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RME Stock 12 Month Forecast
There Are No Analyst Ratings for CH:RME In The Last 3 Months.
| Highest Price Target― | Average Price Target― | Lowest Price Target― |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
RME Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Robert W. Baird
CHF257.56→CHF241.46
Buy
―
Reiterated
11/03/25
UBS
CHF261.58→CHF269.63
Buy
―
Reiterated
11/03/25
Piper Sandler
CHF217.32
Hold
―
Reiterated
10/31/25
Oppenheimer
―
Hold
―
Reiterated
10/31/25
Mizuho Securities
CHF249.51→CHF241.46
Buy
―
Reiterated
10/31/25
Morgan Stanley
CHF244.68→CHF245.49
Buy
―
Reiterated
10/31/25
Resmed's Strong Financial Performance and Growth Potential Justify Buy RatingWe estimate that an additional buy-back of US$1bn (or a total of US$400mn per quarter) would provide EPS accretion of ~2%. Retain OW: We continue to see a favourable growth outlook for RMD, supported by increased uptake in addressable markets, reflecting increased diagnosis and awareness of OSA. Our long-term growth forecasts capture the potential impacts associated with GLP-1s. Combined with valuation appeal relative to our sector coverage, a solid balance sheet position and attractive ROIC, we retain OW.
William Blair
―
Buy
―
Reiterated
10/31/25
RBC Capital
CHF241.46→CHF243.88
Buy
―
Reiterated
10/31/25
TR | OpenAI - 4o
CHF248.71→CHF226.17
Buy
―
Reiterated
10/31/25
AI Generated ArticleAI Generated Article
Wells Fargo
CHF225.36
Hold
―
Initiated
10/13/25
Citi
CHF265.61
Buy
―
Reiterated
09/30/25
Bank of America Securities
CHF241.46
Buy
―
Reiterated
09/24/25
Stifel Nicolaus
―
Hold
―
Reiterated
08/13/25
We remain Hold‐rated on Resmed (RMD, $283.29, Hold) within our Sleep segment commentary.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Robert W. Baird
CHF257.56→CHF241.46
Buy
―
Reiterated
11/03/25
UBS
CHF261.58→CHF269.63
Buy
―
Reiterated
11/03/25
Piper Sandler
CHF217.32
Hold
―
Reiterated
10/31/25
Oppenheimer
―
Hold
―
Reiterated
10/31/25
Mizuho Securities
CHF249.51→CHF241.46
Buy
―
Reiterated
10/31/25
Morgan Stanley
CHF244.68→CHF245.49
Buy
―
Reiterated
10/31/25
Resmed's Strong Financial Performance and Growth Potential Justify Buy RatingWe estimate that an additional buy-back of US$1bn (or a total of US$400mn per quarter) would provide EPS accretion of ~2%. Retain OW: We continue to see a favourable growth outlook for RMD, supported by increased uptake in addressable markets, reflecting increased diagnosis and awareness of OSA. Our long-term growth forecasts capture the potential impacts associated with GLP-1s. Combined with valuation appeal relative to our sector coverage, a solid balance sheet position and attractive ROIC, we retain OW.
William Blair
―
Buy
―
Reiterated
10/31/25
RBC Capital
CHF241.46→CHF243.88
Buy
―
Reiterated
10/31/25
TR | OpenAI - 4o
CHF248.71→CHF226.17
Buy
―
Reiterated
10/31/25
AI Generated ArticleAI Generated Article
Wells Fargo
CHF225.36
Hold
―
Initiated
10/13/25
Citi
CHF265.61
Buy
―
Reiterated
09/30/25
Bank of America Securities
CHF241.46
Buy
―
Reiterated
09/24/25
Stifel Nicolaus
―
Hold
―
Reiterated
08/13/25
We remain Hold‐rated on Resmed (RMD, $283.29, Hold) within our Sleep segment commentary.
Best Analysts Covering Resmed
1 Month
xxx
Success Rate
13/21 ratings generated profit
Average Return
+4.24%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.90% of your transactions generating a profit, with an average return of +4.24% per trade.
3 Months
xxx
Success Rate
7/10 ratings generated profit
Average Return
+3.54%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +3.54% per trade.
1 Year
Success Rate
8/10 ratings generated profit
Average Return
+5.88%
reiterated a buy rating 9 days ago
Copying Craig Wong-Pan's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +5.88% per trade.
2 Years
xxx
Success Rate
20/25 ratings generated profit
Average Return
+20.53%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +20.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RME Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
0
0
0
0
0
Buy
11
20
28
29
19
Hold
2
4
4
8
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
24
32
37
23
Each month's total comprises the sum of three months' worth of ratings.
RME Stock Forecast FAQ
What is CH:RME’s average 12-month price target, according to analysts?
Currently, no data Available
What is CH:RME’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CH:RME, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Resmed Inc a Buy, Sell or Hold?
Currently, no data Available
What is Resmed Inc’s share price target?
Currently, no data Available
What do analysts say about Resmed Inc?
Not enough analysts have published a price target to provide an average price target.
How can I buy shares of Resmed Inc?
To buy shares of CH:RME, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.